Literature DB >> 32134754

The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation.

Angels Barberà1,2, Ruth Marginet Flinch2, Montserrat Martin2, Jose L Mate2, Albert Oriol3, Fina Martínez-Soler1, Tomas Santalucia1, Pedro L Fernández2.   

Abstract

Humanized antibodies targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have been approved for the treatment of different cancers. Some of these antibodies show a correlation between the tissue expression of PD-L1 and response. Evaluation of PD-L1 expression presents multiple challenges, but some preanalytical issues such as tissue fixation have been scarcely evaluated. With the hypothesis that immunohistochemical staining of PD-L1 may be impacted by the time of specimen fixation, we evaluated differences in its expression in tonsil samples exposed to predefined fixation times. Random nontumoral tonsillectomy specimens were blindly evaluated in tissue microarray slides after staining with SP142 and SP263 antibodies. With fixation times ranging from 12 to 72 hours, between 2.8% and 6.1% of the samples were considered to be suboptimally stained, with no differences between the 2 antibodies within these fixation times. A significantly higher proportion of samples exposed to a fixation time of 96 hours presented suboptimal immunostaining (15.6%, P<0.0001). In addition, suboptimally stained spots were 20.8% using SP142 and 10.4% using SP263 after 96 hours of fixation (P=0.046). In conclusion, the quality of staining for PD-L1 in tonsil samples decreased with overfixation of the specimen at times >72 hours. Samples exposed to formaldehyde for longer periods presented suboptimal results for both clones, but the SP142 antibody presented a significantly lower tolerance to formalin overexposure than SP263. These results indicate the relevance of a controlled preanalytical processing of samples and particularly the length of fixation of tumor specimens.

Entities:  

Year:  2021        PMID: 32134754     DOI: 10.1097/PAI.0000000000000847

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  3 in total

1.  γH2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma.

Authors:  Eiko Sakurai; Hisato Ishizawa; Yuka Kiriyama; Ayano Michiba; Yasushi Hoshikawa; Tetsuya Tsukamoto
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

2.  The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC.

Authors:  Mari Mino-Kenudson; Nolwenn Le Stang; Jillian B Daigneault; Andrew G Nicholson; Wendy A Cooper; Anja C Roden; Andre L Moreira; Erik Thunnissen; Mauro Papotti; Giuseppe Pelosi; Noriko Motoi; Claudia Poleri; Elisabeth Brambilla; Mary Redman; Deepali Jain; Sanja Dacic; Yasushi Yatabe; Ming Sound Tsao; Fernando Lopez-Rios; Johan Botling; Gang Chen; Teh-Ying Chou; Fred R Hirsch; Mary Beth Beasley; Alain Borczuk; Lukas Bubendorf; Jin-Haeng Chung; David Hwang; Dongmei Lin; John Longshore; Masayuki Noguchi; Natasha Rekhtman; Lynette Sholl; William Travis; Akihiko Yoshida; Murry W Wynes; Ignacio I Wistuba; Keith M Kerr; Sylvie Lantuejoul
Journal:  J Thorac Oncol       Date:  2021-03-02       Impact factor: 20.121

3.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Cristina Magi-Galluzzi; Sofia Cañete-Portillo; Alcides Chaux; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Daniel Athanazio; Jatin Gandhi; Alberto Cavazza; Giacomo Santandrea; Alessandro Tafuni; Magda Zanelli
Journal:  Cells       Date:  2021-11-14       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.